{"protocolSection": {"identificationModule": {"nctId": "NCT01836471", "orgStudyIdInfo": {"id": "CQAW039A2214"}, "secondaryIdInfos": [{"id": "2012-003995-38", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients", "officialTitle": "A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy"}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-05"}, "primaryCompletionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-17", "studyFirstSubmitQcDate": "2013-04-17", "studyFirstPostDateStruct": {"date": "2013-04-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-01-30", "resultsFirstSubmitQcDate": "2017-01-30", "resultsFirstPostDateStruct": {"date": "2017-03-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-01-30", "lastUpdatePostDateStruct": {"date": "2017-03-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.", "detailedDescription": "This was a multi-centre, randomised, placebo-controlled, double blind, 3-arm study designed to compare the efficacy and safety of a once daily dose of QAW039 with placebo in non-atopic and atopic asthmatics both inadequately controlled despite receiving a low dose ICS background therapy, over a 12 week treatment period. Efficacy and safety of a once daily dose of QAW039 was also compared with an increased dose of ICS in atopic asthmatics taking low dose ICS as background therapy."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 345, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QAW039 450 mg qd Non-atopic", "type": "EXPERIMENTAL", "description": "QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.", "interventionNames": ["Drug: QAW039", "Drug: Fluticasone 100 mcg"]}, {"label": "Placebo Non-atopic", "type": "PLACEBO_COMPARATOR", "description": "Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 \u03bcg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.", "interventionNames": ["Drug: Placebo QAW039", "Drug: Fluticasone 100 mcg"]}, {"label": "QAW039 450 mg qd Atopic", "type": "EXPERIMENTAL", "description": "QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1", "interventionNames": ["Drug: QAW039", "Drug: Fluticasone 100 mcg"]}, {"label": "Fluticasone 150 mcg bid Atopic", "type": "ACTIVE_COMPARATOR", "description": "Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 \u03bcg ICS and with background ICS (100 \u03bcg fluticasone, bid). As a consequence total ICS was 250 \u03bcg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1", "interventionNames": ["Drug: Placebo QAW039", "Drug: Fluticasone 250 mcg"]}, {"label": "Placebo Atopic", "type": "PLACEBO_COMPARATOR", "description": "Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 \u03bcg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1", "interventionNames": ["Drug: Placebo QAW039", "Drug: Fluticasone 100 mcg"]}], "interventions": [{"type": "DRUG", "name": "QAW039", "description": "QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)", "armGroupLabels": ["QAW039 450 mg qd Atopic", "QAW039 450 mg qd Non-atopic"]}, {"type": "DRUG", "name": "Placebo QAW039", "description": "Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)", "armGroupLabels": ["Fluticasone 150 mcg bid Atopic", "Placebo Atopic", "Placebo Non-atopic"]}, {"type": "DRUG", "name": "Fluticasone 250 mcg", "description": "Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).", "armGroupLabels": ["Fluticasone 150 mcg bid Atopic"]}, {"type": "DRUG", "name": "Fluticasone 100 mcg", "description": "Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).", "armGroupLabels": ["Placebo Atopic", "Placebo Non-atopic", "QAW039 450 mg qd Atopic", "QAW039 450 mg qd Non-atopic"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Trough FEV1 (L) in Non-atopic Patients at Week 12 - Full Analysis Set", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug.\n\nData within 6 hr of rescue medication use is excluded from this analysis. For subjects with missing trough FEV1 (L) at Week 12, the last post baseline observation were used (LOCF).\n\nEstimates are from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline trough FEV1 and region as fixed effects and center nested within region as random effects. Full analysis set included all randomized subjects who received at least one dose of study drug.", "timeFrame": "baseline,12 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Trough FEV1 (L) in Atopic Patients at Week 12 - Full Analysis Set", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the FEV1 measurement taken prior to the first dose of randomized study drug.\n\nData within 6 hr of rescue medication use is excluded from this analysis. For subjects with missing trough FEV1 (L) at Week 12, the last post baseline observation were used (LOCF).\n\nEstimates are from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline trough FEV1 and region as fixed effects and center nested within region as random effects. Full analysis set included all randomized subjects who received at least one dose of study drug.", "timeFrame": "baseline,12 weeks"}, {"measure": "Change From Baseline in Trough FEV1 (L) in Non-atopic Compared to Atopic Patients at Week 12 - Full Analysis Set", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the FEV1 measurement taken prior to the first dose of randomized study drug.\n\nData within 6 hr of rescue medication use is excluded from this analysis. For subjects with missing trough FEV1 (L) at Week 12, the last post baseline observation were used (LOCF).\n\nEstimates are from a mixed effects model with treatment, subject population, treatment by subject population interaction, baseline trough FEV1 and region as fixed effects and center nested within region as random effects. Full analysis set included all randomized subjects who received at least one dose of study drug.", "timeFrame": "baseline,12 weeks"}, {"measure": "Change From Baseline in ACQ-6 Score at Week 12 Non-atopic and Atopic Patients at Week 12 - Full Analysis Set", "description": "ACQ-6 consists of:5 items on symptoms, 1 item on rescue bronchodilator use, and 1 item on airway caliber (FEV1 % predicted). The ACQ was fully validated, including a minimal important difference (MID) or smallest change that could be considered clinically important (0.5). The ACQ was self-administered at the clinic and patients scored each item on a 7-point response scale: 0 = 'totally controlled' and 6 = 'severely uncontrolled.' Study staff scored question 7 based on % predicted FEV1 (ideally pre-bronchodilator). The total score=average of first 6 questions. Baseline=the ACQ-6 measurement taken prior to first dose of randomized study drug. The single missing score was interpolated by utilizing prior or subsequent completions of the questionnaire. Estimates were from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline ACQ-6 and region as fixed effects and center nested within region as random effects.", "timeFrame": "baseline,12 weeks"}, {"measure": "Change From Baseline in ACQ-6 Score at Week 12 Non-atopic Compared to Atopic Patients at Week 12 - Full Analysis Set", "description": "ACQ-6 consists of:5 items on symptoms, 1 item on rescue bronchodilator use, and 1 item on airway caliber (FEV1 % predicted). The ACQ was fully validated, including a minimal important difference (MID) or smallest change that could be considered clinically important (0.5). The ACQ was self-administered at the clinic and patients scored each item on a 7-point response scale: 0 = 'totally controlled' and 6 = 'severely uncontrolled.' Study staff scored question 7 based on % predicted FEV1 (ideally pre-bronchodilator). The total score=average of first 6 questions. Baseline=the ACQ-6 measurement taken prior to first dose of randomized study drug. The single missing score was interpolated by utilizing prior or subsequent completions of the questionnaire. Estimates were from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline ACQ-6 and region as fixed effects and center nested within region as random effects.", "timeFrame": "baseline,12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent must be obtained before any assessment is performed\n* Patients with a diagnosis of persistent asthma (according to Global Initiative for Asthma 2011) for a period of at least 6 months prior to screening\n* Patients with a pre-bronchodilator Forced Expiratory Volume In One Second (FEV1) value of 40% to 80% of individual predicted value at screening and prior to treatment\n* An Asthma Control Questionnaire score \u2265 1.5 prior to treatment\n* Demonstration of reversible airway obstruction\n\nExclusion Criteria:\n\n* Pregnant or nursing (lactating) women\n* Acute illness other than asthma at the start of the study\n* Patients with clinically significant laboratory abnormalities at screening\n* Patients with clinically significant condition which may compromise subject safety or interfere with study evaluation\n* Use of other investigational drugs at the time of enrollment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Richard Kay", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Novartis Investigative Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Novartis Investigative Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigative Site", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigative Site", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Novartis Investigative Site", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Novartis Investigative Site", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Novartis Investigative Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Novartis Investigative Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Novartis Investigative Site", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigative Site", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Novartis Investigative Site", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Novartis Investigative Site", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Sarasota", "state": "Florida", "zip": "34233", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Novartis Investigative Site", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Novartis Investigative Site", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Novartis Investigative Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63128", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Papillion", "state": "Nebraska", "zip": "68046", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Novartis Investigative Site", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Novartis Investigative Site", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Novartis Investigative Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigative Site", "city": "Medford", "state": "Oregon", "zip": "97504-8741", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Novartis Investigative Site", "city": "Portland", "state": "Oregon", "zip": "97213", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Novartis Investigative Site", "city": "Lincoln", "state": "Rhode Island", "zip": "02865", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Novartis Investigative Site", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Novartis Investigative Site", "city": "Seattle", "state": "Washington", "zip": "98104", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Novartis Investigative Site", "city": "Erpent", "zip": "5100", "country": "Belgium", "geoPoint": {"lat": 50.45116, "lon": 4.90557}}, {"facility": "Novartis Investigative Site", "city": "Liege", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Novartis Investigative Site", "city": "Barranquilla", "state": "Atlantico", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Novartis Investigative Site", "city": "Bogot\u00e1", "state": "Cundinamarca", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigative Site", "city": "Barranquilla", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Novartis Investigative Site", "city": "Medell\u00edn", "country": "Colombia", "geoPoint": {"lat": 6.25184, "lon": -75.56359}}, {"facility": "Novartis Investigative Site", "city": "Hradec Kralove", "state": "CZE", "zip": "500 05", "country": "Czech Republic", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"facility": "Novartis Investigative Site", "city": "Karlovy Vary-Stara Rokle", "state": "CZE", "zip": "360 17", "country": "Czech Republic"}, {"facility": "Novartis Investigative Site", "city": "Teplice", "state": "CZE", "zip": "415 01", "country": "Czech Republic", "geoPoint": {"lat": 50.6404, "lon": 13.82451}}, {"facility": "Novartis Investigative Site", "city": "Trutnov", "zip": "541 01", "country": "Czech Republic", "geoPoint": {"lat": 50.56101, "lon": 15.9127}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04357", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "L\u00fcbeck", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Novartis Investigative Site", "city": "Marburg", "zip": "D-35037", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "Novartis Investigative Site", "city": "Wiesbaden", "zip": "65187", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "Witten", "zip": "58452", "country": "Germany", "geoPoint": {"lat": 51.44362, "lon": 7.35258}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Andhra Pradesh", "zip": "500 068", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Panjim", "state": "Goa", "zip": "403 002", "country": "India", "geoPoint": {"lat": 15.49574, "lon": 73.82624}}, {"facility": "Novartis Investigative Site", "city": "Nagpur", "state": "Maharashtra", "zip": "400 012", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigative Site", "city": "Nagpur", "state": "Maharashtra", "zip": "440010", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigative Site", "city": "Coimbatore", "state": "Tamil Nadu", "zip": "641 045", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"facility": "Novartis Investigative Site", "city": "Cheongju-si", "state": "Chungcheongbuk-do", "zip": "28644", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Novartis Investigative Site", "city": "Bucheon-Si", "state": "Gyeonggi-Do", "zip": "14584", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Novartis Investigative Site", "city": "Suwon", "state": "Gyeonggi-do", "zip": "443-721", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Korea", "zip": "06591", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Gwangju", "zip": "501-757", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Novartis Investigative Site", "city": "Bialystok", "zip": "15-010", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novartis Investigative Site", "city": "Bialystok", "zip": "15-044", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novartis Investigative Site", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Novartis Investigative Site", "city": "Wroclaw", "zip": "50-349", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "state": "District 1", "zip": "10457", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "state": "District 3", "zip": "030303", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "state": "District 3", "zip": "030317", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Craiova", "state": "Dolj", "zip": "200515", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Novartis Investigative Site", "city": "Arad", "zip": "310013", "country": "Romania", "geoPoint": {"lat": 46.18333, "lon": 21.31667}}, {"facility": "Novartis Investigative Site", "city": "Craiova", "zip": "200515", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Novartis Investigative Site", "city": "Deva", "zip": "330162", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "Novartis Investigative Site", "city": "Timisoara", "zip": "300736", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7500", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7531", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7925", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "8001", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Durban", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Novartis Investigative Site", "city": "Gatesville", "zip": "7764", "country": "South Africa", "geoPoint": {"lat": -33.97558, "lon": 18.52306}}, {"facility": "Novartis Investigative Site", "city": "Pretoria", "zip": "0181", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Total of 939 subjects were screened, 679 entered the inhaled corticosteroid (ICS) tapering run-in, 345 subjects were randomized; eleven randomized subjects discontinued the study prior to start of study drug. Patient disposition and baseline characteristics were presented for 334 subjects (received study drug)", "groups": [{"id": "FG000", "title": "QAW039 450 mg qd Non-atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "FG001", "title": "Placebo Non-atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "FG002", "title": "QAW039 450 mg qd Atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "FG003", "title": "Fluticasone 150 \u00b5g Bid Atopic", "description": "Fluticasone 150 \u00b5g plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "FG004", "title": "Placebo Atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "93"}, {"groupId": "FG001", "numSubjects": "94"}, {"groupId": "FG002", "numSubjects": "51"}, {"groupId": "FG003", "numSubjects": "42"}, {"groupId": "FG004", "numSubjects": "54"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "82"}, {"groupId": "FG001", "numSubjects": "85"}, {"groupId": "FG002", "numSubjects": "49"}, {"groupId": "FG003", "numSubjects": "40"}, {"groupId": "FG004", "numSubjects": "49"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Non compliance with tx", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "QAW039 450 mg qd Non-atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "BG001", "title": "Placebo Non-atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "BG002", "title": "QAW039 450 mg qd Atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "BG003", "title": "Fluticasone 150 \u00b5g Bid Atopic", "description": "Fluticasone 150 \u00b5g plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "BG004", "title": "Placebo Atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "93"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "51"}, {"groupId": "BG003", "value": "42"}, {"groupId": "BG004", "value": "54"}, {"groupId": "BG005", "value": "334"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.9", "spread": "14.33"}, {"groupId": "BG001", "value": "53.5", "spread": "14.37"}, {"groupId": "BG002", "value": "50.3", "spread": "12.75"}, {"groupId": "BG003", "value": "48.2", "spread": "12.16"}, {"groupId": "BG004", "value": "48.2", "spread": "13.58"}, {"groupId": "BG005", "value": "51.0", "spread": "13.81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "26"}, {"groupId": "BG003", "value": "23"}, {"groupId": "BG004", "value": "25"}, {"groupId": "BG005", "value": "194"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "25"}, {"groupId": "BG003", "value": "19"}, {"groupId": "BG004", "value": "29"}, {"groupId": "BG005", "value": "140"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "13"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "3"}, {"groupId": "BG005", "value": "44"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "1"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "22"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "29"}, {"groupId": "BG004", "value": "43"}, {"groupId": "BG005", "value": "248"}]}]}, {"title": "More than one race", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}]}, {"title": "Unknown or Not Reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "6"}]}]}]}, {"title": "Duration of asthma", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.88", "spread": "12.349"}, {"groupId": "BG001", "value": "12.82", "spread": "12.196"}, {"groupId": "BG002", "value": "24.69", "spread": "17.446"}, {"groupId": "BG003", "value": "27.78", "spread": "18.039"}, {"groupId": "BG004", "value": "24.09", "spread": "16.055"}, {"groupId": "BG005", "value": "18.91", "spread": "15.648"}]}]}]}, {"title": "Subject population", "description": "Non-atopic defined as history of perennial symptoms with no clear inhaled allergic trigger AND a negative skin prick test (\\< 3mm diameter above background) or a negative specific IgE (\\<0.35 IU eq./ml). Atopic/allergic defined as skin prick test (\u2265 3mm diameter above background) or a positive specific IgE (e.g.,RAST/CAP) test (\u22650.35 IU eq/ml)", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Non-atopic", "categories": [{"measurements": [{"groupId": "BG000", "value": "93"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "187"}]}]}, {"title": "Atopic", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "51"}, {"groupId": "BG003", "value": "42"}, {"groupId": "BG004", "value": "54"}, {"groupId": "BG005", "value": "147"}]}]}]}, {"title": "Percentage of predicted FEV1 (%) pre-bronchodilator", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67.5446", "spread": "11.81404"}, {"groupId": "BG001", "value": "65.7286", "spread": "13.94056"}, {"groupId": "BG002", "value": "69.0662", "spread": "12.16292"}, {"groupId": "BG003", "value": "68.7483", "spread": "10.52156"}, {"groupId": "BG004", "value": "64.8709", "spread": "12.97729"}, {"groupId": "BG005", "value": "66.9849", "spread": "12.56166"}]}]}]}, {"title": "ACQ-6 score", "description": "Number of participants (n=92,94,51,42,54)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "points", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.70", "spread": "0.762"}, {"groupId": "BG001", "value": "1.53", "spread": "0.745"}, {"groupId": "BG002", "value": "1.55", "spread": "0.665"}, {"groupId": "BG003", "value": "1.68", "spread": "0.749"}, {"groupId": "BG004", "value": "1.72", "spread": "0.675"}, {"groupId": "BG005", "value": "1.63", "spread": "0.728"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Trough FEV1 (L) in Non-atopic Patients at Week 12 - Full Analysis Set", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug.\n\nData within 6 hr of rescue medication use is excluded from this analysis. For subjects with missing trough FEV1 (L) at Week 12, the last post baseline observation were used (LOCF).\n\nEstimates are from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline trough FEV1 and region as fixed effects and center nested within region as random effects. Full analysis set included all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liter", "timeFrame": "baseline,12 weeks", "groups": [{"id": "OG000", "title": "QAW039 450 mg qd Non-atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "OG001", "title": "Placebo Non-atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "93"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.029"}, {"groupId": "OG001", "value": "0.03", "spread": "0.029"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7269", "statisticalMethod": "Mixed Models Analysis", "paramType": "least squares mean", "paramValue": "0.01", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.5", "ciUpperLimit": "0.08", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.038"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough FEV1 (L) in Atopic Patients at Week 12 - Full Analysis Set", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the FEV1 measurement taken prior to the first dose of randomized study drug.\n\nData within 6 hr of rescue medication use is excluded from this analysis. For subjects with missing trough FEV1 (L) at Week 12, the last post baseline observation were used (LOCF).\n\nEstimates are from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline trough FEV1 and region as fixed effects and center nested within region as random effects. Full analysis set included all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liter", "timeFrame": "baseline,12 weeks", "groups": [{"id": "OG000", "title": "QAW039 450 mg qd Atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG001", "title": "Fluticasone 150 \u00b5g Bid Atopic", "description": "Fluticasone 150 \u00b5g plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG002", "title": "Placebo Atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.038"}, {"groupId": "OG001", "value": "0.01", "spread": "0.042"}, {"groupId": "OG002", "value": "0.05", "spread": "0.037"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "least sqares mean", "paramValue": "0.01", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.09", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "least squares mean", "paramValue": "0.04", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.04", "ciUpperLimit": "0.13", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.054"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "least squares mean", "paramValue": "-0.04", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.13", "ciUpperLimit": "0.05", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough FEV1 (L) in Non-atopic Compared to Atopic Patients at Week 12 - Full Analysis Set", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the FEV1 measurement taken prior to the first dose of randomized study drug.\n\nData within 6 hr of rescue medication use is excluded from this analysis. For subjects with missing trough FEV1 (L) at Week 12, the last post baseline observation were used (LOCF).\n\nEstimates are from a mixed effects model with treatment, subject population, treatment by subject population interaction, baseline trough FEV1 and region as fixed effects and center nested within region as random effects. Full analysis set included all randomized subjects who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liter", "timeFrame": "baseline,12 weeks", "groups": [{"id": "OG000", "title": "QAW039 450 mg qd Non-atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "OG001", "title": "Placebo Non-atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "OG002", "title": "QAW039 450 mg qd Atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG003", "title": "Fluticasone 150 \u00b5g Bid Atopic", "description": "Fluticasone 150 \u00b5g plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG004", "title": "Placebo Atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "50"}, {"groupId": "OG003", "value": "41"}, {"groupId": "OG004", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.029"}, {"groupId": "OG001", "value": "0.03", "spread": "0.029"}, {"groupId": "OG002", "value": "0.06", "spread": "0.038"}, {"groupId": "OG003", "value": "0.01", "spread": "0.042"}, {"groupId": "OG004", "value": "0.05", "spread": "0.037"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9179", "statisticalMethod": "Mixed Models Analysis"}]}, {"type": "SECONDARY", "title": "Change From Baseline in ACQ-6 Score at Week 12 Non-atopic and Atopic Patients at Week 12 - Full Analysis Set", "description": "ACQ-6 consists of:5 items on symptoms, 1 item on rescue bronchodilator use, and 1 item on airway caliber (FEV1 % predicted). The ACQ was fully validated, including a minimal important difference (MID) or smallest change that could be considered clinically important (0.5). The ACQ was self-administered at the clinic and patients scored each item on a 7-point response scale: 0 = 'totally controlled' and 6 = 'severely uncontrolled.' Study staff scored question 7 based on % predicted FEV1 (ideally pre-bronchodilator). The total score=average of first 6 questions. Baseline=the ACQ-6 measurement taken prior to first dose of randomized study drug. The single missing score was interpolated by utilizing prior or subsequent completions of the questionnaire. Estimates were from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline ACQ-6 and region as fixed effects and center nested within region as random effects.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score", "timeFrame": "baseline,12 weeks", "groups": [{"id": "OG000", "title": "QAW039 450 mg qd Non-atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "OG001", "title": "Placebo Non-atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "OG002", "title": "QAW039 450 mg qd Atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG003", "title": "Fluticasone 150 \u00b5g Bid Atopic", "description": "Fluticasone 150 \u00b5g plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG004", "title": "Placebo Atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.077"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.073"}, {"groupId": "OG002", "value": "-0.25", "spread": "0.096"}, {"groupId": "OG003", "value": "-0.35", "spread": "0.104"}, {"groupId": "OG004", "value": "-0.18", "spread": "0.096"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "least squares mean", "paramValue": "-0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.22", "ciUpperLimit": "0.17", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.098"}, {"groupIds": ["OG002", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "least sqares mean", "paramValue": "-0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.32", "ciUpperLimit": "0.19", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.128"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "least squares mean", "paramValue": "0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.16", "ciUpperLimit": "0.37", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.134"}, {"groupIds": ["OG003", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "least squares mean", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.43", "ciUpperLimit": "0.09", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.134"}]}, {"type": "SECONDARY", "title": "Change From Baseline in ACQ-6 Score at Week 12 Non-atopic Compared to Atopic Patients at Week 12 - Full Analysis Set", "description": "ACQ-6 consists of:5 items on symptoms, 1 item on rescue bronchodilator use, and 1 item on airway caliber (FEV1 % predicted). The ACQ was fully validated, including a minimal important difference (MID) or smallest change that could be considered clinically important (0.5). The ACQ was self-administered at the clinic and patients scored each item on a 7-point response scale: 0 = 'totally controlled' and 6 = 'severely uncontrolled.' Study staff scored question 7 based on % predicted FEV1 (ideally pre-bronchodilator). The total score=average of first 6 questions. Baseline=the ACQ-6 measurement taken prior to first dose of randomized study drug. The single missing score was interpolated by utilizing prior or subsequent completions of the questionnaire. Estimates were from a mixed effects model with treatment, subject population (non-atopic vs. atopic), treatment by subject population interaction, baseline ACQ-6 and region as fixed effects and center nested within region as random effects.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score", "timeFrame": "baseline,12 weeks", "groups": [{"id": "OG000", "title": "QAW039 450 mg qd Non-atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "OG001", "title": "Placebo Non-atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1 to QAW039 or placebo."}, {"id": "OG002", "title": "QAW039 450 mg qd Atopic", "description": "QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG003", "title": "Fluticasone 150 \u00b5g Bid Atopic", "description": "Fluticasone 150 \u00b5g plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}, {"id": "OG004", "title": "Placebo Atopic", "description": "Placebo to QAW039 450 mg qd plus background ICS (100 \u03bcg fluticasone, bid). Atopic patients randomized in ratio of approximately 1:1:1 to QAW039 or fluticasone or placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.077"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.073"}, {"groupId": "OG002", "value": "-0.25", "spread": "0.096"}, {"groupId": "OG003", "value": "-0.35", "spread": "0.104"}, {"groupId": "OG004", "value": "-0.18", "spread": "0.096"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7930", "statisticalMethod": "Mixed Models Analysis"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Timeframe for AE", "description": "AE additional description", "eventGroups": [{"id": "EG000", "title": "QAW039 450 mg qd", "description": "QAW039 450 mg qd", "seriousNumAffected": 2, "seriousNumAtRisk": 145, "otherNumAffected": 36, "otherNumAtRisk": 145}, {"id": "EG001", "title": "Fluticasone 150 mcg Bid", "description": "Fluticasone 150 mcg bid", "seriousNumAffected": 0, "seriousNumAtRisk": 42, "otherNumAffected": 19, "otherNumAtRisk": 42}, {"id": "EG002", "title": "Placebo", "description": "Placebo", "seriousNumAffected": 3, "seriousNumAtRisk": 147, "otherNumAffected": 35, "otherNumAtRisk": 147}], "seriousEvents": [{"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "HEPATIC STEATOSIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "ANAPHYLACTIC REACTION", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "PRESYNCOPE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "OVARIAN CYST", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}], "otherEvents": [{"term": "DENTAL CARIES", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "ACUTE SINUSITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 147}]}, {"term": "BRONCHITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 147}]}, {"term": "CONJUNCTIVITIS VIRAL", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 147}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 147}]}, {"term": "ORAL CANDIDIASIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "PHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "RHINITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "SINUSITIS BACTERIAL", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "SKIN INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "TONSILLITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 147}]}, {"term": "VIRAL UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 147}]}, {"term": "LIGAMENT SPRAIN", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "WOUND", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "BLOOD TRIGLYCERIDES INCREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "ELECTROCARDIOGRAM QT PROLONGED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "ARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "MUSCULOSKELETAL PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "SYNOVIAL CYST", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 147}]}, {"term": "SYNCOPE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "HAEMATURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "DYSMENORRHOEA", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 147}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 147}]}, {"term": "PRODUCTIVE COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 147}]}, {"term": "DERMATITIS CONTACT", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "ECZEMA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}, {"term": "ERYTHEMA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (18.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 147}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novaratis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000007210", "term": "Indoleacetic Acids"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000010937", "term": "Plant Growth Regulators"}, {"id": "D000006133", "term": "Growth Substances"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M10254", "name": "Indoleacetic Acids", "asFound": "Renal Dysfunction", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}